Expansion in Hungary: SCHOTT and Hungarian government invest in cutting-edge syringe production
10 March 2022, Lukácsháza, Hungary / Mainz, Germany
- The 76 million Euro (28,044 billion HUF) investment in Hungary is designed to meet the growing global demand for prefillable syringes made of glass.
- The brand new production is planned at SCHOTT’s existing site in Lukácsháza.
Already today, SCHOTT’s Hungarian site in Lukácsháza plays an important role in supplying the global industry with drug containment systems and provides enough space for further capacity expansions to follow.
Building on the strong existing foundation and skillset, the production will be equipped with state-of-the-art machinery. As part of SCHOTT’s global production network in 13 countries, the manufacturing will follow high-end processes and advanced quality assurance.
More information on syriQ® prefillable glass syringes
syriQ® is a registered trademark of SCHOTT AG.
Pioneering – responsibly – togetherThese attributes characterize SCHOTT as a manufacturer of high-tech materials based on specialty glass. Founder Otto Schott is considered its inventor and became the pioneer of an entire industry.Always opening up new markets and applications with a pioneering spirit and passion – this is what has driven the #glasslovers at SCHOTT for more than 130 years. Represented in 34 countries, the company is a highly skilled partner for high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace. In the fiscal year 2021, its 17,300 employees generated sales of 2.5 billion euros. SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest foundations in Germany. It uses the Group's dividends to promote science. As a foundation company, SCHOTT has anchored responsibility for employees, society and the environment deeply in its DNA. The goal is to become a climate-neutral company by 2030.
Public Relations Manager